mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and
Company profile
Ticker
MDWD
Exchange
Website
CEO
Sharon Malka
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MDWD stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company
21 Mar 24
6-K
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12 Feb 24
6-K
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
9 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
MediWound Secures Additional U.S. Department of Defense Funding to
28 Dec 23
6-K
Current report (foreign)
15 Dec 23
6-K
MediWound Reports Third Quarter 2023 Financial Results and Provides
21 Nov 23
6-K
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer
21 Nov 23
6-K
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
13 Nov 23
Transcripts
MDWD
Earnings call transcript
2023 Q4
21 Mar 24
MDWD
Earnings call transcript
2023 Q3
21 Nov 23
MDWD
Earnings call transcript
2023 Q2
16 Aug 23
MDWD
Earnings call transcript
2023 Q1
30 May 23
MDWD
Earnings call transcript
2022 Q4
16 Mar 23
MDWD
Earnings call transcript
2022 Q3
15 Nov 22
MDWD
Earnings call transcript
2022 Q2
10 Aug 22
MDWD
Earnings call transcript
2022 Q1
17 May 22
MDWD
Earnings call transcript
2021 Q4
17 Mar 22
MDWD
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
SC 13G/A
Rosalind Advisors, Inc.
25 Apr 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G/A
Deep Insight Limited Partnership
8 Jan 24
SC 13G/A
Israel Biotech Fund II, L.P.
8 Jan 24
SC 13D/A
Access Industries Holdings LLC
1 Sep 23
SC 13G/A
ROSENBERG LIOR
14 Feb 23
SC 13D/A
Access Industries Holdings LLC
13 Feb 23
SC 13G
Point72 Asset Management, L.P.
8 Feb 23
SC 13G
Rosalind Advisors, Inc.
21 Dec 22
SC 13G
Deep Insight Limited Partnership
5 Dec 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 9 |
Closed positions | 1 |
Increased positions | 5 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 19.72 bn |
Total shares | 15.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Israel Biotech Fund II | 5.72 mm | $9.15 mm |
Deep Insight Limited Partnership | 5.72 mm | $9.15 mm |
Access Industries | 1.49 mm | $20.52 mm |
Point72 Asset Management | 821.50 k | $8.76 bn |
Rosalind Advisors | 444.33 k | $4.75 mm |
DAFNA Capital Management | 257.65 k | $2.75 bn |
Rosenberg Lior | 251.34 k | $0.00 |
Alyeska Investment | 150.00 k | $1.60 bn |
Uniplan Investment Counsel | 147.76 k | $1.58 mm |
AWM Investment | 142.86 k | $1.50 bn |
News
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
22 Mar 24
MediWound Q4 EPS $(0.19) Beats $(0.23) Estimate, Sales $5.34M Beat $5.32M Estimate
21 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Preview: MediWound's Earnings
20 Mar 24
MediWound Announced The Results Of Head-To-Head Comparison Analyses Of EscharEx To Collagenase SANTYL Ointment, Approved By The FDA For Debriding Chronic Dermal Ulcers
12 Feb 24